Karyopharm Therapeutics (NASDAQ:KPTI) Shares Down 9% – Should You Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s stock price traded down 9% on Thursday . The company traded as low as $9.12 and last traded at $8.94. 161,265 shares changed hands during trading, an increase of 112% from the average session volume of 75,959 shares. The stock had previously closed at $9.83.

Analyst Ratings Changes

A number of analysts have issued reports on the company. StockNews.com lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. HC Wainwright boosted their price objective on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday. Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, February 20th. Finally, Piper Sandler lifted their target price on Karyopharm Therapeutics from $60.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $62.75.

Karyopharm Therapeutics Stock Down 4.8 %

The stock has a market cap of $66.94 million, a price-to-earnings ratio of -7.79 and a beta of 0.06. The company’s fifty day moving average is $9.81 and its two-hundred day moving average is $11.24.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. Sell-side analysts predict that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KPTI. Adage Capital Partners GP L.L.C. grew its holdings in shares of Karyopharm Therapeutics by 46.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after purchasing an additional 2,000,000 shares during the last quarter. Marshall Wace LLP grew its stake in Karyopharm Therapeutics by 15.3% during the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock worth $1,633,000 after buying an additional 319,187 shares during the last quarter. GSA Capital Partners LLP grew its stake in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after buying an additional 792,283 shares during the last quarter. Geode Capital Management LLC increased its position in Karyopharm Therapeutics by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock worth $942,000 after buying an additional 36,922 shares during the period. Finally, Jane Street Group LLC lifted its stake in Karyopharm Therapeutics by 265.5% in the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after buying an additional 543,556 shares during the last quarter. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).